{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:56:38Z","timestamp":1789764998008,"version":"4.0.1"},"reference-count":15,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2025,2,24]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The impact of body weight on disability progression rates among patients receiving ofatumumab was not evaluated yet.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Among patients from a multicentre prospective cohort, baseline demographics were compared among body mass index (BMI) quartiles as well as proportions of clinical relapses, MRI lesions and disability worsening during follow-up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>536 patients from four centres were included. Baseline demographics were evenly distributed among patients. Proportions of relapses and new\/enlarging MRI lesions were comparable among BMI strata.<\/jats:p>\n                  <jats:p>Confirmed disability worsening was significantly more abundant among patients from the 4th BMI quartile (BMI \u226529.2\u2009kg\/m<jats:sup>2<\/jats:sup>; adjusted HR: 3.33 (95% CI: 1.72 to 6.42; p&lt;0.001). Relapse-associated worsening was not substantially different among relapsing patients from different BMI strata (HR: 1.19 (95% CI: 0.40 to 3.52; p=0.750)). Yet, progression independent from relapse activity was more likely in patients from 4th BMI quartile (HR: 2.00 (95% CI: 1.47 to 2.70; p&lt;0.001)).<\/jats:p>\n                  <jats:p>Body weight (4th body weight quartile: \u226584.5\u2009kg) was not associated with disability worsening (adjusted HR: 1.91 (95%\u2009CI: 0.97 to 3.76; p=0.060). Ofatumumab serum levels were lower in patients with higher BMI as well.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Inflammatory disease outcomes did not differ but disability progression was more frequent in the highest BMI quartile (BMI &gt;29.2\u2009kg\/m<jats:sup>2<\/jats:sup>). This was associated with lower ofatumumab serum levels. Since body weight itself was not predictive, we assume that body fat composition is critical for ofatumumab effectiveness.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jnnp-2024-335673","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T07:12:28Z","timestamp":1741331548000},"page":"802-806","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Association of body mass index and clinical response in patients receiving ofatumumab for treatment of multiple sclerosis"],"prefix":"10.1136","volume":"96","clinical-trial-number":[{"clinical-trial-number":"nct04544436","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04548999","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Pia","family":"Winter","sequence":"first","affiliation":[{"name":"Department of Neurology, Justus-Liebig-University Giessen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Axhausen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Justus-Liebig-University Giessen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Wolff","sequence":"additional","affiliation":[{"name":"Department of Neurology, Justus-Liebig-University Giessen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice Grizzle","family":"Willison","sequence":"additional","affiliation":[{"name":"Department of Neurology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8901-5572","authenticated-orcid":false,"given":"Saskia","family":"R\u00e4uber","sequence":"additional","affiliation":[{"name":"Department of Neurology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz Felix","family":"Konen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School, Hanover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4439-4374","authenticated-orcid":false,"given":"Stefanie","family":"Schreiber","sequence":"additional","affiliation":[{"name":"Department of Neurology, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Schwenkenbecher","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School, Hanover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Hagler","sequence":"additional","affiliation":[{"name":"Department of Neurology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6332-8650","authenticated-orcid":false,"given":"Tobias","family":"Ruck","sequence":"additional","affiliation":[{"name":"Department of Neurology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagen B","family":"Huttner","sequence":"additional","affiliation":[{"name":"Department of Neurology, Justus-Liebig-University Giessen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kleinschnitz","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Duisburg-Essen, Duisburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Pawlitzki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8550-335X","authenticated-orcid":false,"given":"Thomas","family":"Skripuletz","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School, Hanover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Refik","family":"Pul","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Duisburg-Essen, Duisburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven G","family":"Meuth","sequence":"additional","affiliation":[{"name":"Department of Neurology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5171-4845","authenticated-orcid":false,"given":"Steffen","family":"Pfeuffer","sequence":"additional","affiliation":[{"name":"Department of Neurology, Justus-Liebig-University Giessen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"2025071606150569000_96.8.802.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"2025071606150569000_96.8.802.2","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol"},{"key":"2025071606150569000_96.8.802.3","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200094","article-title":"Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis","volume":"10","author":"Hauser","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025071606150569000_96.8.802.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917246"},{"key":"2025071606150569000_96.8.802.5","doi-asserted-by":"crossref","unstructured":"Kappos L , Montalban X , Coyle P , et al . Ofatumumab Reduces Disability Progression Independent of Relapse Activity in Patients with Relapsing Multiple Sclerosis (2299). Neurology (ECronicon) 2021;96. doi:10.1212\/WNL.96.15_supplement.2299","DOI":"10.1212\/WNL.96.15_supplement.2299"},{"key":"2025071606150569000_96.8.802.6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.11.1444"},{"key":"2025071606150569000_96.8.802.7","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121118"},{"key":"2025071606150569000_96.8.802.8","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00895-w"},{"key":"2025071606150569000_96.8.802.9","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241269219"},{"key":"2025071606150569000_96.8.802.10","doi-asserted-by":"publisher","DOI":"10.4103\/JMU.JMU_34_18"},{"key":"2025071606150569000_96.8.802.11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ddtec.2005.05.006","article-title":"Subcutaneous drug delivery and the role of the lymphatics","volume":"2","author":"McLennan","year":"2005","journal-title":"Drug Discov Today Technol"},{"key":"2025071606150569000_96.8.802.12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.814064","article-title":"Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration","volume":"13","author":"Torres","year":"2022","journal-title":"Front Immunol"},{"key":"2025071606150569000_96.8.802.13","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-329685"},{"key":"2025071606150569000_96.8.802.14","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211061861"},{"key":"2025071606150569000_96.8.802.15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/acn3.50972","article-title":"Confounding effect of blood volume and body mass index on blood neurofilament light chain levels","volume":"7","author":"Manouchehrinia","year":"2020","journal-title":"Ann Clin Transl Neurol"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2024-335673","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T13:15:23Z","timestamp":1752671723000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2024-335673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":15,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,7,16]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/jnnp-2024-335673"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2024-335673","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]}}}